Last edition
News about "STARPATH study"
Ascidian Therapeutics Completes STELLAR Trial Dose Escalation for ACDN-01 in Stargardt Disease
Ascidian Therapeutics completes Phase 1/2 STELLAR dose escalation for ACDN-01 in Stargardt disease, advances pediatric enrollment, and launches STARPATH prescreening to accelerate clinical trial access.
STARPATH Study | 05/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members